Trial reportDiabetes, obesity & metabolism2025
Impact of eligibility for diabetes remission on response to intensive lifestyle intervention in overweight and obese people with type 2 diabetes: The Look AHEAD trial.
Trial report in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of eligibility for diabetes remission on response to intensive lifestyle intervention in overweight and obese people with type 2 diabetes: The Look AHEAD trial.Diabetes, obesity & metabolism · 2025Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
aimsTo achieve remission of type 2 diabetes, resources to support intensive lifestyle intervention (ILI) are directed toward people with diabetes for whom remission is achievable, that is, people with short diabetes duration and lower HbA1c. We aimed to determine if responses to ILI, other than remission, justify this resource allocation. MATERIALS AND
methodsWe analysed participants from the Look AHEAD randomised controlled trial who were 20-65 years old with a BMI of 27-45 kg/m
resultsThere were 3105 participants included-60% women, median age 58 years, and median follow-up time 9 years (IQR 8-10 years). At baseline, 54% were eligible for remission. Remission eligibility status did not modify the effect of ILI on CVD, CKD, or mortality. ILI led to 2.4 kg greater weight loss (-5.53 kg (95% CI -6.02, -5.03) vs. -3.17 kg (95% CI -3.86, -2.49)), and 0.1% greater HbA1c reduction (-0.28% (95% CI -0.33, -0.23) vs. -0.17% (95% CI -0.23, -0.11)) in eligible compared with ineligible people.
conclusionsThe small additional benefit of ILI in people eligible for remission, compared with ineligible people, may not be enough to justify restricting resources for ILI to such eligible people.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.